文献速递糖尿病

一般人群中婴儿肠道微生物组组成与1型糖尿病发生相关:ABIS研究

Infant gut microbiome composition correlated with type 1 diabetes acquisition in the general population: the ABIS study.
PubMed 文献 · Diabetologia · 2023-03-25

在ABIS前瞻性一般人群队列中,对平均12.5月龄婴儿的粪便样本行16S rRNA测序和定量PCR,比较未来1型糖尿病患儿(n=16)与健康对照(n=268)的微生物差异。结果显示,健康对照中Parasutterella和Eubacterium更丰富,而未来1型糖尿病患儿中Porphyromonas更高;健康对照中丁酸产生和丙酮酸发酵相关预测基因更高。研究提示1型糖尿病的微生物标志物可能早至1岁即存在。

要点

  • 健康对照婴儿中Parasutterella和Eubacterium丰度更高。
  • 未来1型糖尿病诊断婴儿中Porphyromonas丰度更高。
  • 健康对照中丁酸产生和丙酮酸发酵相关预测基因更高。

核心结论

  • 本研究提示,1型糖尿病的微生物标志物可能早至1岁即存在,反映在微生物群落分类和功能差异上。
  • 通过改变或促进「健康」肠道微生物组来预防疾病发生的可能性具有吸引力。

研究设计与样本

  • 纵向一般人群队列All Babies In Southeast Sweden(ABIS)中,婴儿在平均12.5月龄提供粪便样本。
  • 样本包括未来1型糖尿病患儿n=16和健康对照n=268,行16S rRNA测序和定量PCR。
  • 分析16例未来1型糖尿病患儿(平均诊断年龄13.3±5.4岁)与32例匹配对照婴儿的100次迭代,对照在20岁前保持健康。
  • 评估分类和核心微生物组水平的差异,并用PICRUSt从16S rRNA扩增子预测功能内容。

主要发现

  • 健康对照婴儿中Parasutterella和Eubacterium更丰富,而未来1型糖尿病诊断婴儿中Porphyromonas差异性地更丰富。
  • 随机森林分析中Ruminococcus是区分健康对照和未来1型糖尿病婴儿的强决定因素,且两组丰度趋势不同。
  • Flavonifractor和UBA1819是区分健康对照的最强因素,在健康对照中丰度高于未来1型糖尿病婴儿。
  • Alistipes(健康对照中更丰富)和Fusicatenibacter(病例与对照丰度模式混合)是区分未来1型糖尿病的最强因素。
  • 健康对照婴儿中丁酸产生和丙酮酸发酵相关预测基因内容差异性地更高。

局限性

  • 研究为观察性设计,原文未报告其他局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

AIMS/HYPOTHESIS: While autoantibodies are traditional markers for type 1 diabetes development, we identified gut microbial biomarkers in 1-year-old infants associated with future type 1 diabetes up to 20 years before diagnosis. METHODS: Infants enrolled in the longitudinal general population cohort All Babies In Southeast Sweden (ABIS) provided a stool sample at a mean age of 12.5 months. Samples (future type 1 diabetes, n=16; healthy controls, n=268) were subjected to 16S ribosomal RNA (rRNA) sequencing and quantitative PCR. Microbial differences at the taxonomic and core microbiome levels were assessed. PICRUSt was used to predict functional content from the 16S rRNA amplicons. Sixteen infants, with a future diagnosis of type 1 diabetes at a mean age of 13.3±5.4 years, and one hundred iterations of 32 matched control infants, who remained healthy up to 20 years of age, were analysed. RESULTS: Parasutterella and Eubacterium were more abundant in healthy control infants, while Porphyromonas was differentially more abundant in infants with future type 1 diabetes diagnosis. Ruminococcus was a strong determinant in differentiating both control infants and those with future type 1 diabetes using random forest analysis and had differing trends of abundance when comparing control infants and those with future type 1 diabetes. Flavonifractor and UBA1819 were the strongest factors for differentiating control infants, showing higher abundance in control infants compared with those with future type 1 diabetes. Alternatively, Alistipes (more abundant in control infants) and Fusicatenibacter (mixed abundance patterns when comparing case and control infants) were the strongest factors for differentiating future type 1 diabetes. Predicted gene content regarding butyrate production and pyruvate fermentation was differentially observed to be higher in healthy control infants. CONCLUSIONS/INTERPRETATION: This investigation suggests that microbial biomarkers for type 1 diabetes may be present as early as 1 year of age, as reflected in the taxonomic and functional differences of the microbial communities. The possibility of preventing disease onset by altering or promoting a 'healthy' gut microbiome is appealing. DATA AVAILABILITY: The forward and reverse 16S raw sequencing data generated in this study are available through the NCBI Sequence Read Archive under BioProject PRJNA875929. Associated sample metadata used for statistical comparison are available in the source data file. R codes used for statistical comparisons and figure generation are available at: https://github.com/PMilletich/T1D_Pipeline .

来源:Diabetologia,查看原文。版权归原作者所有。

引用

  1. Bélteky M, Milletich PL, Ahrens AP, et al. Infant gut microbiome composition correlated with type 1 diabetes acquisition in the general population: the ABIS study. Diabetologia. 2023. PMID: 36964264. doi:10.1007/s00125-023-05895-7

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。